Close Menu

NEW YORK - NeoGenomics announced Friday it has acquired the oncology division assets of genome sequencing company Human Longevity for $37 million.

The purchase was financed via available cash on hand.

Human Longevity's oncology division performs next-generation sequencing services for pharmaceutical customers and generated about $10 million in revenue last year. NeoGenomics said the company expects the oncology division to be slightly dilutive to 2020 adjusted earnings.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.